——————————————————————————–
Cerebral grew explosively from a 2020 launch into one of the largest online mental health platforms in the US, peaking at a reported $4.8 billion valuation in 2021 before a series of regulatory and operational crises forced major restructuring. The DEA and federal prosecutors scrutinized the platform’s ADHD stimulant prescribing practices beginning in 2022, and Cerebral has since exited controlled-substance prescribing entirely. As of 2026, Cerebral operates as a more conventional telehealth platform serving depression, anxiety, and non-stimulant ADHD care under much tighter clinical guidelines. This cerebral review covers what the platform actually does today, current pricing, what changed after the DEA scrutiny and later FTC and DOJ settlements, and how Cerebral compares to Brightside Health, Talkspace, and other competitors. Because regulatory terms and prices change, treat the specifics below as a starting point and verify current details on Cerebral’s own site before enrolling.
What changed at Cerebral after the DEA investigation
Through 2021-2022, Cerebral aggressively marketed ADHD treatment with fast prescribing of Schedule II stimulants like Adderall and Ritalin. Reporting by the Wall Street Journal and others documented inconsistent clinical evaluation processes that produced high rates of stimulant prescribing relative to clinical norms. Federal scrutiny followed in 2022; major pharmacy chains including CVS and Walmart stopped filling Cerebral stimulant prescriptions; Cerebral suspended new Schedule II prescribing in May 2022; and by October 2022 the company announced it would stop prescribing controlled substances altogether.
The company restructured significantly through 2022-2023, including layoffs and leadership changes. Two later settlements shaped the platform that exists today. In April 2024, the Federal Trade Commission announced an action against Cerebral over allegations that it disclosed consumers’ sensitive personal health information to third-party advertising platforms and used hard-to-cancel sign-up practices; Cerebral was ordered to pay roughly $7 million and to stop using or sharing certain health data for most advertising (verify the current figures and terms with the FTC). In November 2024, the U.S. Department of Justice announced a settlement resolving Controlled Substances Act allegations tied to the platform’s earlier prescribing, under which Cerebral agreed not to prescribe controlled substances going forward. For broader telehealth context, see our telehealth guide.
Cerebral’s legal and regulatory timeline at a glance
- 2020: Cerebral launches as a subscription telehealth mental health platform.
- 2021: Rapid growth; reported valuation near $4.8 billion.
- May 2022: Federal scrutiny of ADHD stimulant prescribing; pharmacies restrict fills; Cerebral suspends new Schedule II prescriptions.
- October 2022: Cerebral announces it will stop prescribing controlled substances entirely.
- April 2024: FTC action over sensitive health-data sharing and cancellation practices; roughly $7 million ordered (verify current).
- November 2024: DOJ settlement resolving Controlled Substances Act allegations; Cerebral agrees not to prescribe controlled substances.
The practical takeaway for a patient in 2026 is simple: Cerebral is no longer a source of stimulant prescriptions, and the platform now handles conditions where controlled substances are not part of routine care.
Cerebral pricing in 2026
Published plans generally look like this, though prices and plan names change, so confirm current rates at sign-up. Medication management plan: about $99 per month plus the cost of the medication itself. This typically includes an initial video evaluation, monthly follow-up visits, and asynchronous messaging with the prescriber. A combined medication-and-therapy plan and a therapy-only plan are also offered at higher monthly rates (roughly in the $300s per month for four sessions, subject to change).
Cerebral has offered insurance through partnerships with insurers such as Aetna, Cigna, and Anthem, plus select regional plans, though coverage is narrower than Brightside or Talkspace. In-network visits are billed at standard plan copays. Patients should verify coverage with their specific plan before signing up — Cerebral’s insurance footprint shifted substantially during the 2022-2023 restructuring, and networks continue to change.
Cerebral for ADHD in 2026
ADHD care at Cerebral is fundamentally different from the pre-2022 model. Cerebral does not prescribe Schedule II stimulants such as Adderall, Vyvanse, or Ritalin; that reflects the company’s 2022 exit from controlled substances and the November 2024 DOJ settlement in which it agreed not to prescribe controlled substances. Instead, ADHD support on the platform centers on non-stimulant medications where a clinician judges them appropriate — options such as atomoxetine, guanfacine, viloxazine, or bupropion — along with therapy and coaching.
Patients who specifically need stimulant medication for ADHD will need an in-person clinician or another provider that prescribes controlled substances within current DEA telemedicine rules. Any stimulant prescribing decision is clinician-directed and individualized; it is not something a patient should try to arrange around. If you are an existing patient with questions about your treatment, ask your prescriber directly rather than assuming a plan from an older review. For ADHD-specific care, dedicated platforms and in-person psychiatry have largely filled the niche Cerebral once occupied.
Cerebral for depression and anxiety
The bulk of Cerebral’s current patient base is depression, anxiety, and related conditions where controlled-substance prescribing is not relevant. The clinical model includes an initial evaluation, medication selection from standard antidepressants and non-controlled anti-anxiety medications, and ongoing follow-up. Therapy is offered as an add-on with licensed clinicians. Medication choices and dosing are decided by the treating clinician based on your history; this article does not recommend any specific drug or dose.
The clinical depth is decent but not exceptional. Brightside Health has stronger outcome measurement, more structured medication-selection workflows, and better-integrated therapy-and-medication combinations. Talkspace has a larger therapy network and broader insurance acceptance. Cerebral occupies a middle position. See our Brightside vs Cerebral and Cerebral vs Talkspace comparisons for detail.
What Cerebral does well
The platform’s strengths in 2026 are different from its 2021 strengths. Same-week first-appointment availability is genuine — patients can often be seen within about a week, which is faster than much in-person psychiatric care in many markets. The patient experience and app design are solid, with useful symptom tracking and easy messaging with the care team.
The medication-and-therapy combination plan is reasonably integrated, particularly for depression and anxiety. Patients who want both modalities through one platform get coordinated care that is harder to achieve when running a therapy app plus separate psychiatry. Pricing is competitive with Brightside, though without the same clinical depth.
Where Cerebral falls short
The brand still carries reputational damage from the 2022 events and the subsequent FTC and DOJ settlements. While the clinical practices have materially changed, public trust has not fully recovered, and some clinicians remain skeptical of the platform. For patients comfortable with the current state, this matters less; for patients comparing platforms on reputation and track record, Brightside or Talkspace are easier choices.
The platform’s scope has narrowed since 2022. It no longer prescribes controlled substances, and complex needs — substance use disorder treatment, severe eating disorders, and complicated psychiatric cases — are appropriately outside its scope. Patients with these needs should look at specialized in-person programs rather than Cerebral. Insurance acceptance is also narrower than Brightside or Talkspace, limiting options for some patients.
Cerebral vs Brightside, Talkspace, and BetterHelp
Compared to Brightside Health, Cerebral is similar in pricing and patient experience but weaker on clinical infrastructure and outcome measurement. Brightside is the better choice for clinically rigorous integrated psychiatric care. Compared to Talkspace, Cerebral offers reasonably tight integration of therapy and medication, while Talkspace has broader insurance acceptance and a larger therapist network.
Compared to BetterHelp, Cerebral offers medication management, which BetterHelp does not. For pure therapy without medication, BetterHelp is cheaper and more flexible. For integrated medication-and-therapy care for depression or anxiety, Cerebral offers something BetterHelp cannot. See our detailed Cerebral vs Talkspace head-to-head.
Frequently Asked Questions
Is Cerebral still operating in 2026?
Yes. Cerebral continues to operate after its 2022-2023 restructuring and its 2024 FTC and DOJ settlements. The clinical model is materially different from the pre-2022 platform, with no controlled-substance prescribing and a focus on depression and anxiety care.
Does Cerebral prescribe Adderall?
No. After suspending Schedule II prescribing in 2022, moving away from controlled substances by October 2022, and agreeing in a November 2024 DOJ settlement not to prescribe controlled substances, Cerebral does not prescribe Adderall or other stimulants. ADHD support focuses on non-stimulant options and therapy. If you need stimulant medication, you will need an in-person or other appropriately licensed prescriber. Verify current policy with Cerebral.
Does Cerebral take insurance?
Sometimes, with select insurers that have included Aetna, Cigna, Anthem, and some regional plans. Coverage is narrower than Brightside or Talkspace and changes over time. Verify with your specific plan before signing up.
How is Cerebral different from Brightside?
Brightside has more structured clinical infrastructure, better outcome measurement, and stronger published outcomes data. Cerebral has comparable pricing and patient experience but is generally considered the less clinically rigorous of the two options.
Is Cerebral safe to use?
The platform is subject to HIPAA, its clinicians are licensed, and its prescribing practices changed substantially after 2022. As of 2026, Cerebral aims to meet standard telehealth care expectations for depression and anxiety. As with any telehealth service, appropriateness depends on your individual situation, and it is not a substitute for emergency care. Patients weighing platforms on past reputation may still prefer Brightside or Talkspace.
What if I am in a mental health crisis?
Telehealth subscriptions like Cerebral are not for emergencies. If you or someone else is in crisis or thinking about suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline (available 24/7 in the US), or call 911 if there is immediate danger.
The bottom line on Cerebral
Cerebral in 2026 is a different company than the 2021 platform that grew explosively and then ran into regulatory trouble. It no longer prescribes controlled substances, its data practices are now constrained by an FTC order, and its clinical focus has narrowed to conditions like depression and anxiety. For patients seeking integrated medication and therapy for those conditions, Cerebral is reasonable but not best in class — Brightside Health offers more clinical rigor and better outcome data. For ADHD, and especially for anyone who needs stimulant medication, Cerebral is no longer the right platform, and dedicated ADHD-focused care or in-person psychiatry are better choices. Whatever platform you choose, treatment decisions about therapy and medication should be made with a licensed clinician who knows your history.
TL;DR: Cerebral still operates in 2026 but has exited controlled substances entirely (no Adderall or other stimulants) after its 2022 suspension, a move away from controlled substances by October 2022, and a November 2024 DOJ settlement; a 2024 FTC order also restricts its use of sensitive health data and required a payment of roughly $7 million. It now focuses on depression, anxiety, and non-stimulant ADHD care, with pricing around $99/month and up. Verify current pricing, insurance, and policies directly with Cerebral.
This article is for general education and is not medical advice, a diagnosis, or an endorsement of any platform. Decisions about therapy and medication are individual and should be made with a licensed clinician. Cerebral is not for emergencies — in a mental health crisis, call or text 988, or call 911 for immediate danger. Regulatory settlement figures and terms are summarized from public reporting and may be updated; confirm current details with the FTC and DOJ.
Sources
- Federal Trade Commission — 2024 action and order regarding Cerebral’s handling of sensitive consumer health data and cancellation practices (ftc.gov)
- U.S. Department of Justice — November 2024 settlement resolving Controlled Substances Act allegations involving Cerebral (justice.gov)
- U.S. Drug Enforcement Administration — telemedicine prescribing of controlled substances (dea.gov)
- SAMHSA — 988 Suicide & Crisis Lifeline (988lifeline.org)
- U.S. Department of Health & Human Services, Office for Civil Rights — HIPAA (hhs.gov)